121 related articles for article (PubMed ID: 12432282)
1. Inactivation of tumor suppressor genes by promoter methylation is important in the pathogenesis of pancreatic cancer.
Fleming JB; Minna JD
Cancer Biol Ther; 2002; 1(3):297-9. PubMed ID: 12432282
[No Abstract] [Full Text] [Related]
2. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
Jansen M; Fukushima N; Rosty C; Walter K; Altink R; Heek TV; Hruban R; Offerhaus JG; Goggins M
Cancer Biol Ther; 2002; 1(3):293-6. PubMed ID: 12432281
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation.
Allinen M; Peri L; Kujala S; Lahti-Domenici J; Outila K; Karppinen SM; Launonen V; Winqvist R
Genes Chromosomes Cancer; 2002 Aug; 34(4):384-9. PubMed ID: 12112527
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
Fukami T; Fukuhara H; Kuramochi M; Maruyama T; Isogai K; Sakamoto M; Takamoto S; Murakami Y
Int J Cancer; 2003 Oct; 107(1):53-9. PubMed ID: 12925956
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer.
Fukuhara H; Kuramochi M; Fukami T; Kasahara K; Furuhata M; Nobukuni T; Maruyama T; Isogai K; Sekiya T; Shuin T; Kitamura T; Reeves RH; Murakami Y
Jpn J Cancer Res; 2002 Jun; 93(6):605-9. PubMed ID: 12079507
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis.
Murray PG; Fan Y; Davies G; Ying J; Geng H; Ng KM; Li H; Gao Z; Wei W; Bose S; Anderton J; Kapatai G; Reynolds G; Ito A; Marafioti T; Woodman CB; Ambinder R; Tao Q
Am J Pathol; 2010 Sep; 177(3):1480-90. PubMed ID: 20709797
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines.
Honda T; Tamura G; Waki T; Jin Z; Sato K; Motoyama T; Kawata S; Kimura W; Nishizuka S; Murakami Y
Jpn J Cancer Res; 2002 Aug; 93(8):857-60. PubMed ID: 12716461
[TBL] [Abstract][Full Text] [Related]
10. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
Ueki T; Walter KM; Skinner H; Jaffee E; Hruban RH; Goggins M
Oncogene; 2002 Mar; 21(13):2114-7. PubMed ID: 11960385
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
12. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.
Okami J; Simeone DM; Logsdon CD
Cancer Res; 2004 Aug; 64(15):5338-46. PubMed ID: 15289340
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
14. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
15. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
16. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M
Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic changes in nasopharyngeal carcinoma.
Lo KW; Huang DP
Semin Cancer Biol; 2002 Dec; 12(6):451-62. PubMed ID: 12450731
[TBL] [Abstract][Full Text] [Related]
19. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
20. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis.
Murakami Y
Cancer Sci; 2005 Sep; 96(9):543-52. PubMed ID: 16128739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
